Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancers: dual-antibody combo targets tumors from two angles

NCT ID NCT06924606

Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called JS207, which targets both PD-1 and VEGF, in people with advanced non-small cell lung cancer that got worse after standard chemotherapy and immunotherapy. About 66 participants will receive JS207 alone or combined with another drug (JS004 or docetaxel) to see if it shrinks tumors and controls the disease. The goal is to find a better option for patients who have run out of effective treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) NSCLC that is not amenable to radical surgery or radical radiochemotherapy, or Metastatic or recurrent NSCLC. 2. Subjects with unresectable locally advanced or metastatic or recurrent NSCLC who have failed first-line treatment with PD-1/PD-L1 inhibitors combined with platinum-based doublet chemotherapy (excluding docetaxel); or who have failed sequential first- and second-line treatment with PD-1/PD-L1 inhibitors followed by platinum-based doublet chemotherapy (excluding docetaxel). 3. Subjects must have at least one measurable lesion according to RECIST v1.1. Exclusion Criteria: 1. Histopathologically or cytopathologically confirmed to have combined neuroendocrine component. 2. Sensitivity mutation of EGFR or ALK fusion. 3. Tumor encircles important blood vessels or has obvious necrosis and air space, and the investigator considers that it may cause hemorrhage risk.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced NSCLC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Tumor Hospital of Xinjiang Medical University

    RECRUITING

    Xinjiang, Xinjiang, 830011, China

  • Anyang Tumor Hospital

    RECRUITING

    Anyang, Henan, 455000, China

  • Army Medical Center, PLA

    RECRUITING

    Chongqing, Chongqing Municipality, 400042, China

  • Beijing Chest Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 101100, China

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Heilongjiang, Harbin, 150081, China

  • Hunan Cancer Hospital

    RECRUITING

    Hunan, Changsha, 410031, China

  • Jilin Cancer Hospital

    RECRUITING

    Jilin City, Changchun, 130012, China

  • Second Affiliated Hospital, PLA Academy of Military Medical Sciences

    RECRUITING

    Chongqing, Chongqing Municipality, 400037, China

  • Shanghai Pulmonary Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200433, China

  • Shanghai Pulmonary Hospital

    NOT_YET_RECRUITING

    Shanghai, 200433, China

  • The First Affiliated Hospital of Guangzhou Medical University

    RECRUITING

    Guangdong, Guangzhou, 510120, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    RECRUITING

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Jiangxi, Nanchang, 330000, China

  • The First Affiliated Hospital of Xinxiang Medical University

    RECRUITING

    Xinxiang, Henan, 453100, China

  • The First People's Hospital of Changde

    RECRUITING

    Changde, Hunan, 415003, China

  • The Third People's Hospital of Datong

    RECRUITING

    Datong, Shanxi, 037008, China

  • West China Hospital, Sichuan University

    RECRUITING

    Sichuan, Chengdu, 610044, China

  • Yibin Second People's Hospital

    RECRUITING

    Yibin, Sichuan, 644000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.